To investigate potential differences in the presentation of key clinicopathological features based on diabetic status and treatment group, diabetic CRC patients (n = 194) were compared to non-diabetic CRC patients (n = 78), and the following diabetic treatment groups were compared to one another: diet-controlled (n = 55), metformin-treated (n = 72), insulin-treated (n = 18), other oral antidiabetic agents (n = 4), and combination therapies (n = 35). This evidence concerns the gene INS and colorectal carcinoma.